LONDON – Ananda Pharma PLC (AQSE:ANA), a UK-based biopharmaceutical company, has announced the publication of its Phase 1 pharmacokinetic study on the clinical trial registry clinicaltrials.gov, with the reference number NCT06854783. The study focuses on MRX1, Ananda’s lead investigational cannabidiol (CBD) drug, which is being developed to treat chronic inflammatory pain conditions.
The company, which specializes in creating regulatory approved CBD medicines for complex, chronic conditions, stated that MRX1 is composed of high-purity, pharmaceutical-grade CBD, manufactured to EU GMP quality control standards. The publication of the study is a necessary step towards initiating clinical trials and is intended to ensure transparency and adherence to ethical and international standards.
Ananda Pharma plans to use the data from the trial to bolster its drug development pipeline and support future regulatory submissions, particularly in the U.S. market. Additionally, the company expressed intentions to publish results in high-impact medical journals.
The CEO of Ananda Pharma, Melissa Sturgess, emphasized the company’s dedication to developing CBD medicines that are not only regulatory approved but also accessible to all individuals in need, regardless of their financial situation.
The public listing of the trial details aims to increase visibility and awareness, providing potential participants with information on the trial’s objectives, eligibility criteria, and contact details.
Ananda Pharma collaborates with a team of world-class scientists and key opinion leaders from prestigious institutions such as the University of Edinburgh, Great Ormond Street Hospital for Children, and University College London. The company has been involved in trials funded by NHS England, NHS Scotland, and the National Institute for Health Research (NIHR) for conditions including epilepsy, endometriosis, and chemotherapy-related pain.
This announcement is based on a press release statement and marks a significant milestone for Ananda Pharma as it progresses towards the clinical testing of its CBD-based treatments.
